R&D Global pharmaceutical market projections through 2030 Global pharmaceutical market projections through 2030, with Norstella's Daniel Chancellor.
News US vulnerable to China's API dominance, says report China has such a dominant position in pharmaceutical ingredient production that there is a risk it will weaponise access, says a Congressional report.
News Kelun gets world-first approval for TROP2 ADC Kelun-Biotech has picked up another world-first approval for its TROP2-targeting ADC sac-TMT in non-small cell lung cancer.
News Sanofi grabs Chinese rights to Arrowhead rare disease drug Sanofi has paid $130 million upfront for Chinese rights to an Arrowhead Pharma drug for rare disease familial chylomicronaemia syndrome.
News Bayer files HER2+ lung cancer drug in China Bayer files its oral HER2+ lung cancer drug in China, as it extends a race to market with rival Boehringer Ingelheim.
News AZ taps Chinese firm CSPC's AI acumen in $5.2bn+ alliance AstraZeneca taps China's CSPC Pharma for new drug candidates a second time – and the latest AI-focused alliance is a big one.
Patients LSX2026: On promise and patience, with Hans Schambye At LSX World Congress 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Hans Schambye, CEO of BOOST Pharma.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
